Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases

Schizophrenia Research

Volumn 186, Issue , 2017, Pages 19-28

  Mucci, Armida ^a   Merlotti, Eleonora ^a   Üçok, Alp ^b   Aleman, André ^c   Galderisi, Silvana ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ISTANBUL UNIVERSITY   (Turkey)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Deficit schizophrenia; Electrophysiology; Neurocognition; Neuroimaging; Persistent negative symptoms; Real life functioning

Indexed keywords

CYCLOSERINE; DEXTRO SERINE; GLYCINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; ZOTEPINE;

BRAIN ELECTROPHYSIOLOGY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL OUTCOME; COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONGITUDINAL STUDY; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PERSISTENT NEGATIVE SYMPTOM; POSITIVE SYNDROME; PRACTICE GUIDELINE; PREVALENCE; PRIMARY AND PERSISTENT NEGATIVE SYMPTOM; PRIORITY JOURNAL; RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE; BRAIN; COMPLICATION; DIAGNOSTIC IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

BRAIN; COGNITION DISORDERS; HUMANS; NEUROBIOLOGY; NEUROIMAGING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84969920340     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.05.014     Document Type: Review

References (168)

1. Addington, D., Addington, J., Maticka-Tyndale, E., Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 22 (1993), 39–44.
2. Ahmed, A.O., Strauss, G.P., Buchanan, R.W., Kirkpatrick, B., Carpenter, W.T., Are negative symptoms dimensional or categorical? Detection and validation of deficit schizophrenia with taxometric and latent variable mixture models. Schizophr. Bull. 41:4 (2015), 879–891.
3. Amador, X.F., Kirkpatrick, B., Buchanan, R.W., Carpenter, W.T., Marcinko, L., Yale, S.A., Stability of the diagnosis of deficit syndrome in schizophrenia. Am. J. Psychiatry 156:4 (1999), 637–639.
4. Arango, C., Kirkpatrick, B., Buchanan, R.W., Neurological signs and the heterogeneity of schizophrenia. Am. J. Psychiatry 157:4 (2000), 560–565.
5. Arango, C., Garibaldi, G., Marder, S.R., Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr. Res. 150:2-3 (2013), 346–352.
6. Atbaşoglu, E.C., Ozgüven, H.D., Olmez, S., Dissociation between inattentiveness during mental status testing and social inattentiveness in the Scale for the Assessment of Negative Symptoms attention subscale. Psychopathology 36:5 (2003), 263–268.
7. Avery, R., Startup, M., Calabria, K., The role of effort, cognitive expectancy appraisals and coping style in the maintenance of the negative symptoms of schizophrenia. Psychiatry Res. 167:1-2 (2009), 36–46.
8. Ayesa-Arriola, R., Rodríguez-Sánchez, J.M., Pérez-Iglesias, R., González-Blanch, C., Pardo-García, G., Tabares-Seisdedos, R., Vázquez-Barquero, J.L., Crespo-Facorro, B., The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: a 3 year longitudinal study. Psychiatry Res. 209:3 (2013), 302–308.
9. Balleine, B.W., O'Doherty, J.P., Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 35:1 (2010), 48–69.
10. Barch, D.M., Treadway, M.T., Schoen, N., Effort, anhedonia, and function in schizophrenia: reduced effort allocation predicts amotivation and functional impairment. J. Abnorm. Psychol. 123:2 (2014), 387–397.
11. Bassett, D.S., Bullmore, E., Verchinski, B.A., Mattay, V.S., Weinberger, D.R., Meyer-Lindenberg, A., Hierarchical organization of human cortical networks in health and schizophrenia. J. Neurosci. 28:37 (2008), 9239–9248.
12. Blanchard, J.J., Horan, W.P., Collins, L.M., Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia?. Schizophr. Res. 77:2-3 (2005), 151–165.
13. Bodnar, M., Hovington, C.L., Buchy, L., Malla, A.K., Joober, R., Lepage, M., Cortical thinning in temporo-parietal junction (TPJ) in non-affective first-episode of psychosis patients with persistent negative symptoms. PLoS One, 9(6), 2014, e101372.
14. Bottlender, R., Jäger, M., Groll, C., Strauss, A., Möller, H.J., Deficit states in schizophrenia and their association with the length of illness and gender. Eur. Arch. Psychiatry Clin. Neurosci. 251:6 (2001), 272–278.
15. Boutros, N.N., Mucci, A., Vignapiano, A., Galderisi, S., Electrophysiological aberrations associated with negative symptoms in schizophrenia. Curr. Top. Behav. Neurosci. 21 (2014), 129–156.
16. Breier, A., Buchanan, R.W., Kirkpatrick, B., Davis, O.R., Irish, D., Summerfelt, A., Carpenter, W.T. Jr., Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 151:1 (1994), 20–26.
17. Bryson, G., Whelahan, H.A., Bell, M., Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res. 102:1 (2001), 29–37.
18. Bucci, P., Mucci, A., Merlotti, E., Volpe, U., Galderisi, S., Induced gamma activity and event-related coherence in schizophrenia. Clin. EEG Neurosci. 38:2 (2007), 96–104.
19. Bucci, P., Mucci, A., Piegari, G., Nobile, M., Pini, S., Rossi, A., Vita, A., Galderisi, S., Maj, M., Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. Schizophr. Res., 2016 (Epub ahead of print).
20. Buchanan, R.W., Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 33:4 (2007), 1013–1022.
21. Buchanan, R.W., Kirkpatrick, B., Heinrichs, D.W., Carpenter, W.T. Jr., Clinical correlates of the deficit syndrome of schizophrenia. Am. J. Psychiatry 147:3 (1990), 290–294.
22. Buchanan, R.W., Breier, A., Kirkpatrick, B., Elkashef, A., Munson, R.C., Gellad, F., Carpenter, W.T. Jr., Structural abnormalities in deficit and nondeficit schizophrenia. Am. J. Psychiatry 150:1 (1993), 59–65.
23. Buchanan, R.W., Strauss, M.E., Kirkpatrick, B., Holstein, C., Breier, A., Carpenter, W.T. Jr., Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch. Gen. Psychiatry 51:10 (1994), 804–811.
24. Buchanan, R.W., Breier, A., Kirkpatrick, B., Ball, P., Carpenter, W.T. Jr., Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 155:6 (1998), 751–760.
25. Buchanan, R.W., Javitt, D.C., Marder, S.R., Schooler, N.R., Gold, J.M., McMahon, R.P., Heresco-Levy, U., Carpenter, W.T., The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164:10 (2007), 1593–1602.
26. Buchanan, R.W., Keefe, R.S., Umbricht, D., Green, M.F., Laughren, T., Marder, S.R., The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?. Schizophr. Bull. 37:6 (2011), 1209–1217.
27. Bustillo, J.R., Thaker, G., Buchanan, R.W., Moran, M., Kirkpatrick, B., Carpenter, W.T., Visual information-processing impairments in deficit and nondeficit schizophrenia. Am. J. Psychiatry 154:5 (1997), 647–654.
28. Carpenter, W.T. Jr., Heinrichs, D.W., Wagman, A.M., Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 145:5 (1988), 578–583.
29. Cascella, N.G., Testa, S.M., Meyer, S.M., Rao, V.A., Diaz-Asper, C.M., Pearlson, G.D., Schretlen, D.J., Neuropsychological impairment in deficit vs. non-deficit schizophrenia. J. Psychiatr. Res. 42:11 (2008), 930–937.
30. Cascella, N.G., Fieldstone, S.C., Rao, V.A., Pearlson, G.D., Sawa, A., Schretlen, D.J., Gray-matter abnormalities in deficit schizophrenia. Schizophr. Res. 120:1-3 (2010), 63–70.
31. Chang, W.C., Hui, C.L., Tang, J.Y., Wong, G.H., Lam, M.M., Chan, S.K., Chen, E.Y., Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr. Res. 133:1-3 (2011), 22–28.
32. Chang, W.C., Ming Hui, C.L., Yan Wong, G.H., Wa Chan, S.K., Ming Lee, E.H., Hai Chen, E.Y., Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study. J. Clin. Psychiatry 74:11 (2013), 1046–1053.
33. Cimmer, C., Szendi, I., Csifcsák, G., Szekeres, G., Ambrus Kovács, Z., Somogyi, I., Benedek, G., Janka, Z., Kéri, S., Abnormal neurological signs, visual contrast sensitivity, and the deficit syndrome of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30:7 (2006), 1225–1230.
34. Cohen, A.S., Docherty, N.M., Deficit versus negative syndrome in schizophrenia: prediction of attentional impairment. Schizophr. Bull. 30:4 (2004), 827–835.
35. Cohen, A.S., Saperstein, A.M., Gold, J.M., Kirkpatrick, B., Carpenter, W.T. Jr., Buchanan, R.W., Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr. Bull. 33:5 (2007), 1201–1212.
36. Cohen, A.S., Brown, L.A., Minor, K.S., The psychiatric symptomatology of deficit schizophrenia: a meta-analysis. Schizophr. Res. 118:1-3 (2010), 122–127.
37. Dickerson, F., Kirkpatrick, B., Boronow, J., Stallings, C., Origoni, A., Yolken, R., Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr. Bull. 32:2 (2006), 396–400.
38. Dollfus, S., Germain-Robin, S., Chabot, B., Brazo, P., Delamillieure, P., Langlois, S., van der Eist, A., Campion, D., Petit, M., Family history and obstetric complications in deficit and non-deficit schizophrenia: preliminary results. Eur. Psychiatry 13:5 (1998), 270–272.
39. Edwards, J., McGorry, P.D., Waddell, F.M., Harrigan, S.M., Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophr. Res. 40:2 (1999), 147–158.
40. Evensen, J., Røssberg, J.I., Barder, H., Haahr, U., Hegelstad, W.T., Joa, I., Johannessen, J.O., Larsen, T.K., Melle, I., Opjordsmoen, S., Rund, B.R., Simonsen, E., Sundet, K., Vaglum, P., Friis, S., McGlashan, T., Apathy in first episode psychosis patients: a ten year longitudinal follow-up study. Schizophr. Res. 136:1-3 (2012), 19–24.
41. Farkas, M., Polgar, P., Kelemen, O., Rethelyi, J., Bitter, I., Myers, C.E., Gluck, M.A., Keri, S., Associative learning in deficit and nondeficit schizophrenia. Neuroreport 19:1 (2008), 55–58.
42. Fenton, W.S., McGlashan, T.H., Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am. J. Psychiatry 151:3 (1994), 351–356.
43. Fenton, W.S., Wyatt, R.J., McGlashan, T.H., Risk factors for spontaneous dyskinesia in schizophrenia. Arch. Gen. Psychiatry 51:8 (1994), 643–650.
44. Fervaha, G., Foussias, G., Agid, O., Remington, G., Amotivation and functional outcomes in early schizophrenia. Psychiatry Res. 210:2 (2013), 665–668.
45. Fervaha, G., Agid, O., Foussias, G., Siddiqui, I., Takeuchi, H., Remington, G., Neurocognitive impairment in the deficit subtype of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2015.
46. Fervaha, G., Duncan, M., Foussias, G., Agid, O., Faulkner, G.E., Remington, G., Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizophr. Res. 168:1-2 (2015), 483–490.
47. Fisher, D.J., Labelle, A., Knott, V.J., Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr. Res. 139:1-3 (2012), 237–245.
48. Fornito, A., Zalesky, A., Pantelis, C., Bullmore, E.T., Schizophrenia, neuroimaging and connectomics. NeuroImage 62:4 (2012), 2296–2314.
49. Foussias, G., Remington, G., Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 36:2 (2010), 359–369.
50. Foussias, G., Agid, O., Fervaha, G., Remington, G., Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur. Neuropsychopharmacol. 24:5 (2014), 693–709.
51. Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., McGuire, P., Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr. Bull. 41:4 (2015), 892–899.
52. Galderisi, S., Maj, M., Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur. Psychiatry 24:8 (2009), 493–500.
53. Galderisi, S., Maj, M., Mucci, A., Cassano, G.B., Invernizzi, G., Rossi, A., Vita, A., Dell'Osso, L., Daneluzzo, E., Pini, S., Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am. J. Psychiatry 159:6 (2002), 983–990.
54. Galderisi, S., Quarantelli, M., Volpe, U., Mucci, A., Cassano, G.B., Invernizzi, G., Rossi, A., Vita, A., Pini, S., Cassano, P., Daneluzzo, E., De Peri, L., Stratta, P., Brunetti, A., Maj, M., Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr. Bull. 34:2 (2008), 393–401.
55. Galderisi, S., Bucci, P., Mucci, A., Kirkpatrick, B., Pini, S., Rossi, A., Vita, A., Maj, M., Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr. Res. 147:1 (2013), 157–162.
56. Galderisi, S., Mucci, A., Bitter, I., Libiger, J., Bucci, P., Fleischhacker, W.W., Kahn, R.S., Eufest Study Group, Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur. Neuropsychopharmacol. 22 (2013), 196–204.
57. Galderisi, S., Rossi, A., Rocca, P., Bertolino, A., Mucci, A., Bucci, P., Rucci, P., Gibertoni, D., Aguglia, E., Amore, M., Bellomo, A., Biondi, M., Brugnoli, R., Dell'Osso, L., De Ronchi, D., Di Emidio, G., Di Giannantonio, M., Fagiolini, A., Marchesi, C., Monteleone, P., Oldani, L., Pinna, F., Roncone, R., Sacchetti, E., Santonastaso, P., Siracusano, A., Vita, A., Zeppegno, P., Maj, M., The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 13:3 (2014), 275–287.
58. Gallagher, B.J., Jones, B.J., McFalls, J.A. Jr., Pisa, A.M., Schizophrenic subtype, seasonality of birth and social class: a preliminary analysis. Eur. Psychiatry 22:2 (2007), 123–128.
59. Gerbaldo, H., Georgi, K., Pieschl, D., The deficit syndrome in first-admission patients with psychotic and non-psychotic disorders. Eur. Psychiatry 12:2 (1997), 53–57.
60. Goetz, R.R., Corcoran, C., Yale, S., Stanford, A.D., Kimhy, D., Amador, X., Malaspina, D., Validity of a ‘proxy’ for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr. Res. 93:1-3 (2007), 169–177.
61. Goff, D.C., Tsai, G., Manoach, D.S., Coyle, J.T., Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152:8 (1995), 1213–1215.
62. Goff, D.C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D.A., Hayden, D.L., McCarley, R., Coyle, J.T., A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56:1 (1999), 21–27.
63. Goff, D.C., Bottiglieri, T., Arning, E., Shih, V., Freudenreich, O., Evins, A.E., Henderson, D.C., Baer, L., Coyle, J., Folate, homocysteine, and negative symptoms in schizophrenia. Am. J. Psychiatry 161:9 (2004), 1705–1708.
64. Gonul, A.S., Kula, M., Esel, E., Tutus, A., Sofuoglu, S., A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res. 123:3 (2003), 199–205.
65. Gonzalez-Valderrama, A., Castaneda, C.P., Mena, C., Undurraga, J., Mondaca, P., Yanez, M., Bedregal, P., Nachar, R., Duration of untreated psychosis and acute remission of negative symptoms in a South American first-episode psychosis cohort. Early Interv. Psychiatry, 2015.
66. Gorissen, M., Sanz, J.C., Schmand, B., Effort and cognition in schizophrenia patients. Schizophr. Res. 78:2-3 (2005), 199–208.
67. Hartmann, M.N., Hager, O.M., Reimann, A.V., Chumbley, J.R., Kirschner, M., Seifritz, E., Tobler, P.N., Kaiser, S., Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort. Schizophr. Bull. 41 (2015), 503–512.
68. Harvey, P.D., Koren, D., Reichenberg, A., Bowie, C.R., Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 32:2 (2006), 250–258.
69. Heckers, S., Goff, D., Schacter, D.L., Savage, C.R., Fischman, A.J., Alpert, N.M., Rauch, S.L., Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch. Gen. Psychiatry 56:12 (1999), 1117–1123.
70. Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G., Lichtenstein, M., Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56:1 (1999), 29–36.
71. Hong, L.E., Avila, M.T., Adami, H., Elliot, A., Thaker, G.K., Components of the smooth pursuit function in deficit and nondeficit schizophrenia. Schizophr. Res. 63:1-2 (2003), 39–48.
72. Horga, G., Cassidy, C.M., Xu, X., Moore, H., Slifstein, M., Van Snellenberg, J.X., Abi-Dargham, A., Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia. JAMA Psychiatry, 2016.
73. Hovington, C.L., Lepage, M., Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert. Rev. Neurother. 12:1 (2012), 53–69.
74. Hovington, C.L., Bodnar, M., Joober, R., Malla, A.K., Lepage, M., Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry, 12, 2012, 224.
75. Hovington, C.L., Bodnar, M., Joober, R., Malla, A.K., Lepage, M., Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms. Schizophr. Res. 147:2-3 (2013), 223–229.
76. Howes, O.D., Kapur, S., The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr. Bull. 35:3 (2009), 549–562.
77. Kallel, L., Brunelin, J., Zghal, A., Labbane, R., Dalery, J., d'Amato, T., Saoud, M., Summer birth and deficit schizophrenia in Tunisia. Psychiatry Res. 152:2-3 (2007), 273–275.
78. Kinon, B.J., Noordsy, D.L., Liu-Seifert, H., Gulliver, A.H., Ascher-Svanum, H., Kollack-Walker, S., Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 26:5 (2006), 453–461.
79. Kirkpatrick, B., Recognizing primary vs secondary negative symptoms and apathy vs expression domains. J. Clin. Psychiatry, 75(4), 2014, e09.
80. Kirkpatrick, B., Galderisi, S., Deficit schizophrenia: an update. World Psychiatry 7:3 (2008), 143–147.
81. Kirkpatrick, B., Buchanan, R.W., McKenney, P.D., Alphs, L.D., Carpenter, W.T. Jr., The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30 (1989), 119–123.
82. Kirkpatrick, B., Buchanan, R.W., Breier, A., Carpenter, W.T. Jr., Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 47:1 (1993), 47–56.
83. Kirkpatrick, B., Buchanan, R.W., Breier, A., Carpenter, W.T. Jr., Depressive symptoms and the deficit syndrome of schizophrenia. J. Nerv. Ment. Dis. 182:8 (1994), 452–455.
84. Kirkpatrick, B., Ram, R., Bromet, E., The deficit syndrome in the Suffolk County Mental Health Project. Schizophr. Res. 22:2 (1996), 119–126.
85. Kirkpatrick, B., Amador, X.F., Flaum, M., Yale, S.A., Gorman, J.M., Carpenter, W.T. Jr., Tohen, M., McGlashan, T., The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr. Res. 20:1-2 (1996), 69–77.
86. Kirkpatrick, B., Ram, R., Amador, X.F., Buchanan, R.W., McGlashan, T., Tohen, M., Bromet, E., Summer birth and the deficit syndrome of schizophrenia. Am. J. Psychiatry 155:9 (1998), 1221–1226.
87. Kirkpatrick, B., Castle, D., Murray, R.M., Carpenter, W.T. Jr., Risk factors for the deficit syndrome of schizophrenia. Schizophr. Bull. 26:1 (2000), 233–242.
88. Kirkpatrick, B., Buchanan, R.W., Ross, D.E., Carpenter, W.T. Jr., A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 58:2 (2001), 165–171.
89. Kirkpatrick, B., Tek, C., Allardyce, J., Morrison, G., McCreadie, R.G., Summer birth and deficit schizophrenia in Dumfries and Galloway, southwestern Scotland. Am. J. Psychiatry 159:8 (2002), 1382–1387.
90. Kirkpatrick, B., Fenton, W.S., Carpenter, W.T. Jr., Marder, S.R., The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32:2 (2006), 214–219.
91. Kirkpatrick, B., Strauss, G.P., Nguyen, L., Fischer, B.A., Danie, D.G., Cienfuegos, A., Marder, S.R., The brief negative symptom scale: psychometric properties. Schizophr. Bull. 37:2 (2011), 300–305.
92. Kirschner, M., Hager, O.M., Bischof, M., Hartmann, M.N., Kluge, A., Seifritz, E., Tobler, P.N., Kaiser, S., Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia. J. Psychiatry Neurosci. 41:3 (2016), 152–161.
93. Kitis, O., Ozalay, O., Zengin, E.B., Haznedaroglu, D., Eker, M.C., Yalvac, D., Oguz, K., Coburn, K., Gonul, A.S., Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. Psychiatry Clin. Neurosci. 66:1 (2012), 34–43.
94. Kopelowicz, A., Zarate, R., Tripodis, K., Gonzalez, V., Mintz, J., Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am. J. Psychiatry 157:6 (2000), 987–993.
95. Kring, A.M., Gur, R.E., Blanchard, J.J., Horan, W.P., Reise, S.P., The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am. J. Psychiatry 170:2 (2013), 65–172.
96. Lahti, A.C., Holcomb, H.H., Medoff, D.R., Weiler, M.A., Tamminga, C.A., Carpenter, W.T. Jr., Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am. J. Psychiatry 158:11 (2001), 1797–1808.
97. Larsen, T.K., Melle, I., Auestad, B., Haahr, U., Joa, I., Johannessen, J.O., Opjordsmoen, S., Rund, B.R., Rossberg, J.I., Simonsen, E., Vaglum, P., Friis, S., McGlashan, T., Early detection of psychosis: positive effects on 5-year outcome. Psychol. Med. 41:7 (2011), 1461–1469.
98. Leucht, S., Pitschel-Walz, G., Engel, R.R., Kissling, W., Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 159:2 (2002), 180–190.
99. Li, Z., Zheng, B., Deng, W., Liu, X., Zheng, Z., Li, T., Multi-components of evoked-brain potentials in deficit and nondeficit schizophrenia. Asia Pac. Psychiatry 5 (2013), 69–79.
100. Li, Z., Deng, W., Liu, X., Zheng, Z., Li, M., Li, Y., Han, Y., Ma, X., Wang, Q., Liu, X., Li, T., Contingent negative variation in patients with deficit schizophrenia or bipolar I disorder with psychotic features: measurement and correlation with clinical characteristics. Nord. J. Psychiatry 69:3 (2015), 196–203.
101. Lindenmayer, J.P., Khan, A., Iskander, A., Abad, M.T., Parker, B., A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J. Clin. Psychiatry 68:3 (2007), 368–379.
102. Lubeiro, A., Rueda, C., Hernández, J.A., Sanz, J., Sarramea, F., Molina, V., Identification of two clusters within schizophrenia with different structural, functional and clinical characteristics. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016), 79–86.
103. Ludewig, K., Vollenweider, F.X., Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Med. Wkly. 132:13-14 (2002), 159–165.
104. Mäkinen, J., Miettunen, J., Isohanni, M., Koponen, H., Negative symptoms in schizophrenia: a review. Nord. J. Psychiatry 62:5 (2008), 334–341.
105. Malaspina, D., Coleman, E., Goetz, R.R., Harkavy-Friedman, J., Corcoran, C., Amador, X., Yale, S., Gorman, J.M., Odor identification, eye tracking and deficit syndrome schizophrenia. Biol. Psychiatry 51:10 (2002), 809–815.
106. Malla, A.K., Takhar, J.J., Norman, R.M., Manchanda, R., Cortese, L., Haricharan, R., Verdi, M., Ahmed, R., Negative symptoms in first episode non-affective psychosis. Acta Psychiatr. Scand. 105:6 (2002), 431–439.
107. Malla, A.K., Norman, R.M., Takhar, J., Manchanda, R., Townsend, L., Scholten, D., Haricharan, R., Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis?. J. Nerv. Ment. Dis. 192 (2004), 455–463.
108. Marder, S.R., Kirkpatrick, B., Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur. Neuropsychopharmacol. 24:5 (2014), 737–743.
109. Marder, S.R., Daniel, D.G., Alphs, L., Awad, A.G., Keefe, R.S., Methodological issues in negative symptom trials. Schizophr. Bull. 37:2 (2011), 250–254.
110. Mayerhoff, D.I., Loebel, A.D., Alvir, J.M., Szymanski, S.R., Geisler, S.H., Borenstein, M., Lieberman, J.A., The deficit state in first-episode schizophrenia. Am. J. Psychiatry 151:10 (1994), 1417–1422.
111. Messias, E., Kirkpatrick, B., Summer birth and the deficit syndrome of schizophrenia in The Epidemiological Catchment Area study. J. Nerv. Ment. Dis. 189 (2001), 608–612.
112. Messias, E., Kirkpatrick, B., Bromet, E., Ross, D., Buchanan, R.W., Carpenter, W.T. Jr., Tek, C., Kendler, K.S., Walsh, D., Dollfus, S., Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch. Gen. Psychiatry 61:10 (2004), 985–989.
113. Milev, P., Ho, B.C., Arndt, S., Andreasen, N.C., Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162 (2005), 495–506.
114. Miller, E.M., Shankar, M.U., Knutson, B., McClure, S.M., Dissociating motivation from reward in human striatal activity. J. Cogn. Neurosci. 26:5 (2014), 1075–1084.
115. Möller, H.J., Riedel, M., Müller, N., Fischer, W., Kohnen, R., Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 37:6 (2004), 270–278.
116. Morra, L.F., Gold, J.M., Sullivan, S.K., Strauss, G.P., Predictors of neuropsychological effort test performance in schizophrenia. Schizophr. Res. 162:1-3 (2015), 205–210.
117. Morris, R.W., Quail, S., Griffiths, K.R., Green, M.J., Balleine, B.W., Corticostriatal control of goal-directed action is impaired in schizophrenia. Biol. Psychiatry 77:2 (2015), 187–195.
118. Mucci, A., Galderisi, S., Kirkpatrick, B., Bucci, P., Volpe, U., Merlotti, E., Centanaro, F., Catapano, F., Maj, M., Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophr. Res. 92:1-3 (2007), 252–261.
119. Mucci, A., Dima, D., Soricelli, A., Volpe, U., Bucci, P., Frangou, S., Prinster, A., Salvatore, M., Galderisi, S., Maj, M., Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychol. Med. 45:8 (2015), 1765–1778.
120. Mucci, A., Galderisi, S., Merlotti, E., Rossi, A., Rocca, P., Bucci, P., Piegari, G., Chieffi, M., Vignapiano, A., Maj, M., Italian Network for Research on Psychoses, The Brief Negative Symptom Scale (BNSS): independent validation in a large sample of Italian patients with schizophrenia. Eur. Psychiatry 30:5 (2015), 641–647.
121. Murphy, B.P., Chung, Y.C., Park, T.W., McGorry, P.D., Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr. Res. 88:1-3 (2006), 5–25.
122. Nkam, I., Thibaut, F., Denise, P., Van Der Elst, A., Segard, L., Brazo, P., Menard, J., Thery, S., Halbeck, I., Delamilleure, P., Vasse, T., Etard, O., Dollfus, S., Champion, D., Levillain, D., Petit, M., Saccadic and smooth-pursuit eye movements in deficit and non-deficit schizophrenia. Schizophr. Res. 48:1 (2001), 145–153.
123. Nkam, I., Bocca, M.L., Denise, P., Paoletti, X., Dollfus, S., Levillain, D., Thibaut, F., Impaired smooth pursuit in schizophrenia results from prediction impairment only. Biol. Psychiatry 67:10 (2010), 992–997.
124. Olie, J.P., Spina, E., Murray, S., Yang, R., Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 21:3 (2006), 143–151.
125. Palmiter, R.D., Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice. Ann. N. Y. Acad. Sci. 1129 (2008), 35–46.
126. Peralta, V., Cuesta, M.J., The deficit syndrome of the psychotic illness. A clinical and nosological study. Eur. Arch. Psychiatry Clin. Neurosci. 254:3 (2004), 165–171.
127. Peralta, V., Moreno-Izco, L., Sanchez-Torres, A., García de Jalón, E., Campos, M.S., Cuesta, M.J., Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr. Bull. 40:1 (2014), 214–224.
128. Polgár, P., Farkas, M., Nagy, O., Kelemen, O., Réthelyi, J., Bitter, I., Myers, C.E., Gluck, M.A., Kéri, S., How to find the way out from four rooms? The learning of “chaining” associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophr. Res. 99:1-3 (2008), 200–207.
129. Polgár, P., Réthelyi, J.M., Balint, S., Komlosi, S., Czobor, P., Bitter, I., Executive function in deficit schizophrenia: what do the dimensions of the Wisconsin Card Sorting Test tell us?. Schizophr. Res. 122:1-3 (2010), 85–93.
130. Quarantelli, M., Larobina, M., Volpe, U., Amati, G., Tedeschi, E., Ciarmiello, A., Brunetti, A., Galderisi, S., Alfano, B., Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. NeuroImage 17:1 (2002), 373–384.
131. Rabinowitz, J., Werbeloff, N., Caers, I., Mandel, F.S., Stauffer, V., Menard, F., Kinon, B.J., Kapur, S., Negative symptoms in schizophrenia–the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophr. Res. 150:2-3 (2013), 334–338.
132. Radua, J., Schmidt, A., Borgwardt, S., Heinz, A., Schlagenhauf, F., McGuire, P., Fusar-Poli, P., Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. JAMA Psychiatry 72:12 (2015), 1243–1251.
133. Réthelyi, J.M., Czobor, P., Polgar, P., Mersich, B., Balint, S., Jekkel, E., Magyar, K., Meszaros, A., Fabian, A., Bitter, I., General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 262:2 (2012), 107–115.
134. Riedel, M., Muller, N., Strassnig, M., Spellmann, I., Engel, R.R., Musil, R., Dehning, S., Douhet, A., Schwarz, M.J., Moller, H.J., Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 255:6 (2005), 432–437.
135. Rosenheck, R., Evans, D., Herz, L., Cramer, J., Xu, W., Thomas, J., Henderson, W., Charney, D., How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr. Bull. 25:4 (1999), 709–719.
136. Ross, D.E., Thaker, G.K., Buchanan, R.W., Lahti, A.C., Medoff, D., Bartko, J.J., Moran, M., Hartley, J., Association of abnormal smooth pursuit eye movements with the deficit syndrome in schizophrenic patients. Am. J. Psychiatry 153:9 (1996), 1158–1165.
137. Ross, D.E., Thaker, G.K., Buchanan, R.W., Kirkpatrick, B., Lahti, A.C., Medoff, D., Bartko, J.J., Goodman, J., Tien, A., Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome. Biol. Psychiatry 42:9 (1997), 781–796.
138. Ross, D.E., Buchanan, R.W., Medoff, D., Lahti, A.C., Thaker, G.K., Association between eye tracking disorder in schizophrenia and poor sensory integration. Am. J. Psychiatry 155:10 (1998), 1352–1357.
139. Ross, D.E., Kirkpatrick, B., Karkowski, L.M., Straub, R.E., MacLean, C.J., O'Neill, F.A., Compton, A.D., Murphy, B., Walsh, D., Kendler, K.S., Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am. J. Psychiatry 157:7 (2000), 1071–1076.
140. Rowland, L.M., Spieker, E.A., Francis, A., Barker, P.B., Carpenter, W.T., Buchanan, R.W., White matter alterations in deficit schizophrenia. Neuropsychopharmacology 34:6 (2009), 1514–1522.
141. Roy, M.A., Mérette, C., Maziade, M., Subtyping schizophrenia according to outcome or severity: a search for homogeneous subgroups. Schizophr. Bull. 27:1 (2001), 115–138.
142. Roy, M.A., Maziade, M., Labbé A., Mérette, C., Male gender is associated with deficit schizophrenia: a meta-analysis. Schizophr. Res. 47:2-3 (2001), 141–147.
143. Santos, J.L., Sánchez-Morla, E.M., Aparicio, A., García-Jiménez, M.A., Villanueva, C., Martínez-Vizcaíno, V., Arango, C., P50 gating in deficit and nondeficit schizophrenia. Schizophr. Res. 119:1-3 (2010), 183–190.
144. Skudlarski, P., Jagannathan, K., Anderson, K., Stevens, M.C., Calhoun, V.D., Skudlarska, B.A., Pearlson, G., Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol. Psychiatry 68:1 (2010), 61–69.
145. Spalletta, G., De Rossi, P., Piras, F., Iorio, M., Dacquino, C., Scanu, F., Girardi, P., Caltagirone, C., Kirkpatrick, B., Chiapponi, C., Brain white matter microstructure in deficit and non-deficit subtypes of schizophrenia. Psychiatry Res. 231:3 (2015), 252–261.
146. Stauffer, V.L., Song, G., Kinon, B.J., Ascher-Svanum, H., Chen, L., Feldman, P.D., Conley, R.R., Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr. Res. 134:2-3 (2012), 195–201.
147. Strauss, G.P., Harrow, M., Grossman, L.S., Rosen, C., Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr. Bull. 36:4 (2010), 788–799.
148. Strauss, G.P., Morra, L.F., Sullivan, S.K., Gold, J.M., The role of low cognitive effort and negative symptoms in neuropsychological impairment in schizophrenia. Neuropsychology 29:2 (2015), 282–291.
149. Subotnik, K.L., Nuechterlein, K.H., Ventura, J., Green, M.F., Hwang, S.S., Prediction of the deficit syndrome from initial deficit symptoms in the early course of schizophrenia. Psychiatry Res. 80:1 (1998), 53–59.
150. Subotnik, K.L., Nuechterlein, K.H., Ventura, J., MMPI discriminators of deficit vs. non-deficit recent-onset schizophrenia patients. Psychiatry Res. 93:2 (2000), 111–123.
151. Tamminga, C.A., Thaker, G.K., Buchanan, R., Kirkpatrick, B., Alphs, L.D., Chase, T.N., Carpenter, W.T., Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry 49:7 (1992), 522–530.
152. Tek, C., Kirkpatrick, B., Buchanan, R.W., A five-year follow up study of deficit and nondeficit schizophrenia. Schizophr. Res. 49:3 (2001), 253–260.
153. Telfer, S., Shivashankar, S., Krishnadas, R., McCreadie, R.G., Kirkpatrick, B., Tardive dyskinesia and deficit schizophrenia. Acta Psychiatr. Scand. 124:5 (2011), 357–362.
154. Ten Velden Hegelstad, W., Haahr, U., Larsen, T.K., Auestad, B., Barder, H., Evensen, J., Joa, I., Johannessen, J.O., Langeveld, J., Melle, I., Opjordsmoen, S., Rossberg, J.I., Rund, B.R., Simonsen, E., Vaglum, P., McGlashan, T., Friis, S., Early detection, early symptom progression and symptomatic remission after ten years in a first episode of psychosis study. Schizophr. Res. 143:2-3 (2013), 337–343.
155. Tiryaki, A., Yazici, M.K., Anil, A.E., Kabakçi, E., Karaağaoğlu, E., Göğüş A., Reexamination of the characteristics of the deficit schizophrenia patients. Eur. Arch. Psychiatry Clin. Neurosci. 253:5 (2003), 221–227.
156. Turetsky, B., Cowell, P.E., Gur, R.C., Grossman, R.I., Shtasel, D.L., Gur, R.E., Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch. Gen. Psychiatry 52 (1995), 1061–1070.
157. Turetsky, B.I., Colbath, E.A., Gur, R.E., P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol. Psychiatry 43:2 (1998), 84–96.
158. Üçok, A., Ergül, C., Persistent negative symptoms after first episode schizophrenia: a 2-year follow-up study. Schizophr. Res. 158:1-3 (2014), 241–246.
159. Vaiva, G., Cottencin, O., Llorca, P.M., Devos, P., Dupont, S., Mazas, O., Rascle, C., Thomas, P., Steinling, M., Goudemand, M., Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26:3 (2002), 481–485.
160. Ventura, K.L., Gitlin, M.J., Gretchen-Doorly, D., Ered, A., Villa, K.F., Hellemann, G.S., Nuechterlein, K.H., Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr. Res. 161:2-3 (2015), 407–413.
161. Vogel, S.J., Strauss, G.P., Allen, D.N., Using negative feedback to guide behavior: impairments on the first 4 cards of the Wisconsin Card Sorting Test predict negative symptoms of schizophrenia. Schizophr. Res. 151:1-3 (2013), 97–101.
162. Voineskos, A.N., Foussias, G., Lerch, J., Felsky, D., Remington, G., Rajji, T.K., Lobaugh, N., Pollock, B.G., Mulsant, B.H., Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 70:5 (2013), 472–480.
163. Volpe, U., Mucci, A., Quarantelli, M., Galderisi, S., Maj, M., Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 37:2 (2012), 264–269.
164. Wang, X., Yao, S., Kirkpatrick, B., Shi, C., Yi, J., Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Res. 158:2 (2008), 195–205.
165. Wheeler, A.L., Wessa, M., Szeszko, P.R., Foussias, G., Chakravarty, M.M., Lerch, J.P., DeRosse, P., Remington, G., Mulsant, B.H., Linke, J., Malhotra, A.K., Voineskos, A.N., Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. JAMA Psychiatry 72:5 (2015), 446–455.
166. Yu, M., Tang, X., Wang, X., Zhang, X., Zhang, X., Sha, W., Yao, S., Shu, N., Zhang, X., Zhang, Z., Neurocognitive impairments in deficit and non-deficit schizophrenia and their relationships with symptom dimensions and other clinical variables. PLoS One, 10(9), 2015, e0138357.
167. Yung, A.R., Phillips, L.J., Yuen, H.P., McGorry, P.D., Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 67:2-3 (2004), 131–142.
168. Zalesky, A., Fornito, A., Seal, M.L., Cocchi, L., Westin, C.F., Bullmore, E.T., Egan, G.F., Pantelis, C., Disrupted axonal fiber connectivity in schizophrenia. Biol. Psychiatry 69:1 (2011), 80–89.